CM Management’s Cognition Therapeutics CGTX Stock Holding History

CM Management’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$518K	Buy	450,000 +50,000	+13%	+$59.2K	0.33%	66
2026 Q1	$304K	Buy	400,000 +200,000	+100%	+$233K	0.25%	68
2025 Q4	$270K	Buy	+200,000	New	+$325K	0.23%	60
2025 Q3	–	Sell	-250,000	Closed	-$77.5K	–	69
2025 Q2	$77.5K	Sell	250,000 -150,000	-38%	-$50.6K	0.07%	67
2025 Q1	$168K	Buy	400,000 +200,000	+100%	+$118K	0.17%	54
2024 Q4	$140K	Sell	200,000 -50,000	-20%	-$24.7K	0.13%	56
2024 Q3	$117K	Buy	250,000 +50,000	+25%	+$51.5K	0.09%	64
2024 Q2	$332K	Buy	200,000 +25,000	+14%	+$49.8K	0.3%	58
2024 Q1	$319K	Buy	+175,000	New	+$361K	0.27%	63

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

CM Management's CGTX Position: Q2 2026 in Review

CM Management increased its Cognition Therapeutics (CGTX) stake by 13% in Q2 2026, buying an estimated $59.2K and bringing the position to 450,000 shares worth $518K. The position accounts for 0.33% of the portfolio, ranked #66.

CM Management first reported a position in CGTX in Q1 2024 and has held it in 9 quarters since. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

CM Management held 450,000 shares of Cognition Therapeutics worth $518K as of Q2 2026.
CM Management bought 50,000 Cognition Therapeutics shares in Q2 2026, an estimated $59.2K.
Cognition Therapeutics made up 0.33% of CM Management's portfolio in Q2 2026, its #66 holding.
CM Management first reported a position in Cognition Therapeutics in Q1 2024 and has held it in 9 quarters since.
66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.